Search Results

Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, announced that members of Recludix’s management will host meetings at two investor conferences in March.

Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, today announced that Nancy Whiting, Pharm.D., chief executive officer of Recludix, will present at two investor conferences in February.

Recludix Pharma presented new data today in an oral plenary presentation at the Society for Investigative Dermatology (SID) Annual Meeting titled “Oral selective STAT3 inhibitors demonstrate differentiated efficacy and safety potential in preclinical models of Th17 mediated skin inflammation” (abstract #738).

Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, announced the appointment of Ajay Nirula, M.D., Ph.D., as the company’s executive vice president and head of research and development, and the addition of Adrian S. Ray, Ph.D., to its scientific advisory board.

Recludix Pharma announced that Nancy Whiting, Pharm.D., chief executive officer of Recludix, will present at two investor conferences in November.

Recludix Pharma announced that Nancy Whiting, Pharm.D., chief executive officer of Recludix, will present at multiple investor conferences in September.

Recludix Pharma announced that in a presentation given today titled “Drugging the Undruggable,” Recludix’s senior vice president of biology, Paul Smith, Ph.D., discussed the first application of the company’s platform capabilities to target the Src Homology 2 (SH2) domain, as well as reviewed preclinical data on an early STAT3 inhibitor that was internally discovered through the platform.

Recludix Pharma announced that in a presentation given at the 7th Annual Dermatology Drug Development Summit.